Genmab maps Phase III strategy HuMax-CD20

Denmark's Genmab is laying plans to launch a late-stage study of its closely watched antibody HuMax-CD20 (ofatumumab) as a treatment for rheumatoid arthritis. Licensed by GlaxoSmithKline in a $2.1 billion pact, HuMax-CD20 is also being studied as a potential treatment for blood cancers. The trial will focus on two patient groups, one demonstrating an inadequate response to methotrexate therapy and another group that has had an inadequate response to TNF-alpha antagonist therapy.

"From the data to date, we believe that ofatumumab has real potential," says Genmab CEO Lisa N. Drakeman, Ph.D. "Now that Phase III studies are underway in multiple indications, we are moving closer to realizing this potential and bringing this important treatment to patients."

- take a look at the release for more info

Related Articles:
Glaxo forges $2.1B deal for HuMax-CD20. Report
Genmab reports positive RA data for HuMax-CD20. Report
Genmab shares up on new antibody tech. Report